SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of
incorporation or organization)
(Address of principal executive offices)
Registrant’s telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|Item 5.02.|| |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 10, 2022, CTI BioPharma Corp. (the “Company”) eliminated the position of Chief Operating Officer. Accordingly, Bruce Seeley resigned as Chief Operating Officer, effective as of that date. In connection with his separation from the Company, Mr. Seeley will be entitled to payment of severance benefits pursuant to his severance agreement with the Company (filed as Exhibit 10.11 to the Company’s Form 10-K for the year ended December 31, 2015). The Company wishes to acknowledge Mr. Seeley’s contributions to the approval and launch of VONJO® and is supportive of his pursuit of senior leadership opportunities.
As the commercialization of VONJO transitions from the initial launch phase, Jim Fong, the Company’s Chief Commercial Officer, has been promoted to Executive Vice President and Chief Commercial Officer, and will begin reporting directly to the Company’s Chief Executive Officer. The management functions of the former Chief Operating Officer role have been reassigned to other members of the senior management team.
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|CTI BIOPHARMA CORP.|
|Date: October 13, 2022||By:|
|David H. Kirske|
|Chief Financial Officer|